After the separation, Gilead will hold around 25% of the outstanding shares in both Galapagos and the spin-off company. While ...

Galapagos will gain full development and commercialization rights to its pipeline, and is subject to single digit royalty ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 0.10% of ...

This was the stock's fourth consecutive day of losses.

The beleaguered Belgian firm Galapagos is splitting itself into two companies, with the brandname biotech prioritizing ...

The biotech industry is booming thanks to the rising demand for personalized medicine, investment in innovations, and ongoing ...

TCW Funds, an investment management company, released its “TCW Relative Value Large Cap Fund” Q3 2024 investor letter. A copy ...

This was the stock's third consecutive day of losses.

We came across a bullish thesis on Gilead Sciences, Inc. (NASDAQ:GILD) on Substack by Magnus Ofstad. In this article, we will ...

RBC Capital analyst Brian Abrahams lowered the firm’s price target on Gilead (GILD) to $83 from $84 and keeps a Sector Perform rating on the ...

The biotechnology market experiences significant growth, fueled by advancements in genetic therapies and supportive global ...

Galapagos (GLPG) announced a planned separation into two entities: a newly to be formed company, which would focus on building a pipeline of ...